Cargando…

LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway

BACKGROUND: Adriamycin (ADR) resistance is one of the main obstacles to improving the clinical prognosis of breast cancer patients. Long noncoding RNAs (lncRNAs) can regulate cell behavior, but the role of these RNAs in the anti-ADR activity of breast cancer remains unclear. Here, we aim to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ming, Wang, Yan, Jiang, Longyang, Song, Xinyue, Zheng, Ang, Gao, Hua, Wei, Minjie, Zhao, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830819/
https://www.ncbi.nlm.nih.gov/pubmed/33494806
http://dx.doi.org/10.1186/s13046-021-01844-7
_version_ 1783641500594208768
author Zhang, Ming
Wang, Yan
Jiang, Longyang
Song, Xinyue
Zheng, Ang
Gao, Hua
Wei, Minjie
Zhao, Lin
author_facet Zhang, Ming
Wang, Yan
Jiang, Longyang
Song, Xinyue
Zheng, Ang
Gao, Hua
Wei, Minjie
Zhao, Lin
author_sort Zhang, Ming
collection PubMed
description BACKGROUND: Adriamycin (ADR) resistance is one of the main obstacles to improving the clinical prognosis of breast cancer patients. Long noncoding RNAs (lncRNAs) can regulate cell behavior, but the role of these RNAs in the anti-ADR activity of breast cancer remains unclear. Here, we aim to investigate the imbalance of a particular long noncoding RNA, lncRNA CBR3 antisense RNA 1 (CBR3-AS1), and its role in ADR resistance. METHODS: Microarray analysis of ADR-resistant breast cancer cells was performed to identify CBR3-AS1. CCK-8 and colony formation assays were used to detect the sensitivity of breast cancer cells to ADR. Dual-luciferase reporter, RNA pulldown, IHC and western blot analyses were used to verify the relationship between the expression of CBR3-AS1, miRNA and target genes. For in vivo experiments, the effect of CBR3-AS1 on breast cancer resistance was observed in a xenograft tumor model. The role of CBR3-AS1 in influencing ADR sensitivity was verified by clinical breast cancer specimens from the TCGA, CCLE, and GDSC databases. RESULTS: We found that CBR3-AS1 expression was significantly increased in breast cancer tissues and was closely correlated with poor prognosis. CBR3-AS1 overexpression promoted ADR resistance in breast cancer cells in vitro and in vivo. Mechanistically, we identified that CBR3-AS1 functioned as a competitive endogenous RNA by sponging miR-25-3p. MEK4 and JNK1 of the MAPK pathway were determined to be direct downstream proteins of the CBR3-AS1/miR-25-3p axis in breast cancer cells. CONCLUSIONS: In summary, our findings demonstrate that CBR3-AS1 plays a critical role in the chemotherapy resistance of breast cancer by mediating the miR-25-3p and MEK4/JNK1 regulatory axes. The potential of CBR3-AS1 as a targetable oncogene and therapeutic biomarker of breast cancer was identified. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01844-7.
format Online
Article
Text
id pubmed-7830819
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78308192021-01-26 LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway Zhang, Ming Wang, Yan Jiang, Longyang Song, Xinyue Zheng, Ang Gao, Hua Wei, Minjie Zhao, Lin J Exp Clin Cancer Res Research BACKGROUND: Adriamycin (ADR) resistance is one of the main obstacles to improving the clinical prognosis of breast cancer patients. Long noncoding RNAs (lncRNAs) can regulate cell behavior, but the role of these RNAs in the anti-ADR activity of breast cancer remains unclear. Here, we aim to investigate the imbalance of a particular long noncoding RNA, lncRNA CBR3 antisense RNA 1 (CBR3-AS1), and its role in ADR resistance. METHODS: Microarray analysis of ADR-resistant breast cancer cells was performed to identify CBR3-AS1. CCK-8 and colony formation assays were used to detect the sensitivity of breast cancer cells to ADR. Dual-luciferase reporter, RNA pulldown, IHC and western blot analyses were used to verify the relationship between the expression of CBR3-AS1, miRNA and target genes. For in vivo experiments, the effect of CBR3-AS1 on breast cancer resistance was observed in a xenograft tumor model. The role of CBR3-AS1 in influencing ADR sensitivity was verified by clinical breast cancer specimens from the TCGA, CCLE, and GDSC databases. RESULTS: We found that CBR3-AS1 expression was significantly increased in breast cancer tissues and was closely correlated with poor prognosis. CBR3-AS1 overexpression promoted ADR resistance in breast cancer cells in vitro and in vivo. Mechanistically, we identified that CBR3-AS1 functioned as a competitive endogenous RNA by sponging miR-25-3p. MEK4 and JNK1 of the MAPK pathway were determined to be direct downstream proteins of the CBR3-AS1/miR-25-3p axis in breast cancer cells. CONCLUSIONS: In summary, our findings demonstrate that CBR3-AS1 plays a critical role in the chemotherapy resistance of breast cancer by mediating the miR-25-3p and MEK4/JNK1 regulatory axes. The potential of CBR3-AS1 as a targetable oncogene and therapeutic biomarker of breast cancer was identified. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01844-7. BioMed Central 2021-01-25 /pmc/articles/PMC7830819/ /pubmed/33494806 http://dx.doi.org/10.1186/s13046-021-01844-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Ming
Wang, Yan
Jiang, Longyang
Song, Xinyue
Zheng, Ang
Gao, Hua
Wei, Minjie
Zhao, Lin
LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway
title LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway
title_full LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway
title_fullStr LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway
title_full_unstemmed LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway
title_short LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway
title_sort lncrna cbr3-as1 regulates of breast cancer drug sensitivity as a competing endogenous rna through the jnk1/mek4-mediated mapk signal pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830819/
https://www.ncbi.nlm.nih.gov/pubmed/33494806
http://dx.doi.org/10.1186/s13046-021-01844-7
work_keys_str_mv AT zhangming lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT wangyan lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT jianglongyang lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT songxinyue lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT zhengang lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT gaohua lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT weiminjie lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway
AT zhaolin lncrnacbr3as1regulatesofbreastcancerdrugsensitivityasacompetingendogenousrnathroughthejnk1mek4mediatedmapksignalpathway